Evidence map›Paper›PMID 42625609›Full record

ArticleFrontiers in oncology2026

Emergence of EGFR C797S as a resistance mechanism to CLN081 in EGFR exon 20-mutant NSCLC: case report.

Basil Dabbah, Roni Gillis, Jaber Salim, Adar Yaacov, Bar Cohen, Areen Abu Remilah, Yehonatan Turner, Noam Asna, Nir Peled

Abstract readCase Reports
PubMed Full text at PMC Publisher
In one paragraph

Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors.

Basil Dabbah *Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel.
Roni Gillis *Helmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel.
Jaber SalimHelmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel.
Adar YaacovHelmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel.
Bar CohenHelmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel.
Areen Abu RemilahHelmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel.
Yehonatan TurnerDepartment of Nuclear Medicine, Shaare Zedek Medical Center, Jerusalem, Israel.
Noam AsnaHelmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel.
Nir PeledHelmsley Cancer Center, Shaare Zedek Medical Center, The Hebrew University, Jerusalem, Israel.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

EGFR exon 20 insertion mutations represent a distinct subset of non-small cell lung cancer (NSCLC) with limited sensitivity to earlier-generation EGFR tyrosine kinase inhibitors (TKIs). CLN081 (zipalertinib; TAS6417) is a novel covalent EGFR TKI under development with activity against EGFR exon 20 insertion variants. We report the case of a 44-year-old man with stage IVB lung adenocarcinoma harboring an EGFR exon 20 insertion mutation who received multiple lines of systemic therapy, including CLN081. After eight months of treatment with CLN081, liquid biopsy revealed the emergence of a secondary EGFR C797S mutation (p.Cys797Ser; variant allele frequency [VAF] 0.05%), concurrent with a reduction in the exon 20 insertion allele frequency from 35.1% to 0.5%, accompanied by disease progression. Although C797S-mediated resistance has been hypothesized and demonstrated in preclinical models of CLN081 exposure, this represents, to our knowledge, the first reported

Indexed as

acquired resistancecase reportCLN081EGFR C797SEGFR exon 20 insertionliquid biopsynon–small cell lung cancer

Identifiers

PMID42625609
PMCPMC13489930

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.